Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-23-041255

← back to feed
Filed
Nov 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Nov 14, 2023 65.27M sh
Cash And Equivalents Q1 2024 · Sep 30, 2023 $18.06K
Cash And Equivalents Q1 2024 · Jun 30, 2023 $35.15K
Current Liabilities Q1 2024 · Sep 30, 2023 $312.85K
Current Liabilities Q1 2024 · Jun 30, 2023 $295.13K
Total Liabilities Q1 2024 · Sep 30, 2023 $312.85K
Total Liabilities Q1 2024 · Jun 30, 2023 $295.13K
Current Assets Q1 2024 · Sep 30, 2023 $22.05K
Current Assets Q1 2024 · Jun 30, 2023 $43.13K
Total Assets Q1 2024 · Sep 30, 2023 $22.05K
Total Assets Q1 2024 · Jun 30, 2023 $43.13K
Operating Income Q1 2024 · Sep 30, 2023 $11.37M
Shares Diluted Q1 2024 · Sep 30, 2022 61.07M sh
Operating Cash Flow Q1 2024 · Sep 30, 2022 −$15.75K
Stockholders Equity Q1 2024 · Sep 30, 2022 −$160.6K
Stockholders Equity Q1 2024 · Jun 30, 2022 −$117.61K
Eps Diluted Q1 2024 · Sep 30, 2022 −$0.00
Eps Basic Q1 2024 · Sep 30, 2022 −$0.00
Sga Expense Q1 2024 · Sep 30, 2022 $59.06K
Rd Expense Q1 2024 · Sep 30, 2022 $0
Net Income Q1 2024 · Sep 30, 2022 −$94.87K